Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 26;5(5):e10813.
doi: 10.1371/journal.pone.0010813.

Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations

Affiliations

Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations

Shenying Fang et al. PLoS One. .

Abstract

Background: Previous studies have shown that MDM2 SNP309 and p53 codon 72 have modifier effects on germline P53 mutations, but those studies relied on case-only studies with small sample sizes. The impact of MDM4 polymorphism on tumor onset in germline mutation carriers has not previously been studied.

Methodology/principal findings: We analyzed 213 p53 germline mutation carriers including 168(78.9%) affected with cancer and 174 who had genotypic data. We analyzed time to first cancer using Kaplan-Meier and Cox proportional hazards methods, comparing risks according to polymorphism genotypes. For MDM2 SNP309, a significant difference of 9.0 years in the average age of cancer diagnosis was observed between GG/GT and TT carriers (18.6 versus 27.6 years, P = 0.0087). The hazards ratio was 1.58 (P = 0.03) comparing risks among individuals with GG/GT to risk among TT, but this effect was only significant in females (HR = 1.60, P = 0.02). Compared to other genotypes, P53 codon 72 PP homozygotes had a 2.24 times (P = 0.03) higher rate for time to develop cancer. We observed a multiplicative joint effect of MDM2 and p53 codon72 polymorphism on risk. The MDM4 polymorphism had no significant effects.

Conclusions/significance: Our results suggest that the MDM2 SNP309 G allele is associated with cancer risk in p53 germline mutation carriers and accelerates time to cancer onset with a pronounced effect in females. A multiplicative joint effect exists between the MDM2 SNP309 G allele and the p53 codon 72 G allele in the risk of cancer development. Our results further define cancer risk in carriers of germline p53 mutations.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Kaplan-Meier estimated cumulative incidence for cancer in carriers of a p53 germline mutation by sex.
Observations included 101 males and 112 females (log-rank test P = 0.0057).
Figure 2
Figure 2. Kaplan-Meier estimated cumulative incidence for any cancer in carriers of a p53 germline mutation by mutation type.
Among these 213 carriers(one missing type of mutation), 130 carried a missense mutation and 82 a truncation mutation (deletion 1, nonsense 50, frame-shift 16, splice 15). Log-rank test P = 0.0900.

Similar articles

Cited by

References

    1. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001;114:4139–4140. - PubMed
    1. Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72:975–983. - PMC - PubMed
    1. Malkin D. p53 and the Li-Fraumeni syndrome. Biochim Biophys Acta. 1994;1198:197–213. - PubMed
    1. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Jr, et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 1991;51:6094–6097. - PubMed
    1. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150:1–13. - PMC - PubMed

Publication types

MeSH terms